Aurinia ($AUPH): Can LUPKYNIS Growth Keep Building Cash?

01 Scenarios: what would change the shareholder case

Aurinia is a profitable commercial drug company with a concentrated franchise and a growing development agenda. LUPKYNIS supplies the operating cash; patent outcomes, prescribing growth and investment decisions determine how much of that cash can reach shareholders. The August 19, 2026 Teva settlement improves visibility against one generic challenger, while the August 6 results show a business capable of financing research and repurchases from operations. Those are tangible developments, without making either future sales or clinical success certain. Ownership moved in both directions this year: the chief executive’s investment group bought 814,606 shares between May 29 and June 2, 2026 and wrote put options on another million shares at a $15 strike, while the ILJIN group, a long-standing shareholder, fell below the 5% reporting threshold after sales on August 20. Source Source Source Source

Bull case

The favorable scenario would require LUPKYNIS demand to keep expanding, operating cash generation to remain strong and research investment to produce credible patient evidence. A favorable resolution of further patent disputes would improve confidence in the duration of the franchise. Under those conditions, Aurinia could develop additional assets and return capital without weakening the resources supporting its existing product. The Teva agreement would be one component of that case, rather than a universal guarantee of exclusivity. Source Source

The strongest confirmation would be simultaneous progress in product revenue and cash retained after capital allocation. A higher prescription count would help less if larger rebates, treatment discontinuation or rising expenses absorbed the benefit. Conversely, continued cash generation with disciplined development spending would make the pipeline an opportunity financed by the business, rather than an obligation financed mainly by new shareholders.

Base case

The middle scenario would be continued commercial growth with uneven quarterly cash movements and a gradual increase in research costs. The 2026 sales outlook could remain achievable while new clinical programs still required time to establish their value. Generic litigation would remain a separate uncertainty despite the Teva settlement. In that case, the stock would principally reflect a cash-producing franchise with development optionality, rather than an imminent regulatory binary. Source Source

Repurchases could support per-share economics without causing the reported share count to fall in every period, because employee awards and option exercises also issue shares. The useful comparison would be the net change in ownership and the cash spent to achieve it. A buyback headline alone would not settle that question. Source

Bear case

The adverse scenario would emerge if prescribing growth slowed, competitive or reimbursement pressure reduced the value of each sale, or a patent outcome brought generic competition forward. Research failures or expensive acquisitions could then reduce the cushion provided by LUPKYNIS. A strong starting balance sheet would absorb some pressure, but it would not preserve an unlimited ability to spend, repurchase shares and expand the pipeline simultaneously. Source Source

The most damaging combination would be weaker product economics and greater commitments before a replacement franchise had been established. The company could remain profitable for a time while its longer-term earnings power deteriorated. The converse also matters: an early pipeline disappointment would not by itself erase the approved product or the cash it already generates.

What Would Falsify This Reading

The constructive interpretation depends on sustained commercial cash generation and disciplined use of it. These outcomes would weaken that interpretation.

• Product growth loses cash conversion. If revenue expansion is accompanied by persistently weaker collections, rising rebates or materially higher recurring spending, the cash advantage shown in the June 2026 results would weaken. Source Source
• Patent outcomes become less favorable. An adverse outcome involving another generic challenger, or a defined early-entry contingency, would reduce the visibility implied by the August 19 Teva settlement. Source
• Capital allocation outweighs operating progress. If pipeline commitments, acquisitions and incentive issuance absorb the commercial gains without useful evidence or a lower share count, the benefit to each shareholder would weaken. The June report already shows buybacks and issuance operating simultaneously. Source

These are observations that would weaken the interpretation, not forecasts of inevitable events.

02 The business: one established franchise, several uses for its cash

Aurinia markets LUPKYNIS, or voclosporin, for adults with active lupus nephritis. The drug is used with background immunosuppressive treatment; it is not a standalone cure for every form of lupus. It is a calcineurin inhibitor that affects immune activity and kidney-cell function. That is enough mechanism to understand the investment issue: clinical benefit and tolerability must support repeated use in a disease where kidney damage can accumulate. Source

The company sells directly through its U.S. commercial organization and works with Otsuka in specified international territories. In the June 2026 quarter, net product sales were $79.412 million out of $83.220 million total revenue. The business therefore has an identifiable commercial engine, rather than revenue dominated by a single licensing transaction. Its concentration also means that a change in LUPKYNIS demand, pricing or access can affect most of the operating model. Source

For a trader, the distinction from a pre-revenue biotech is important. The immediate question is less about financing the next few months and more about the durability of earnings, use of accumulated capital and evidence that the next products deserve investment. A healthy balance sheet can support patience, but it does not determine the price investors should pay for that patience.

Lupus nephritis treatment is also becoming more competitive. The annual report identifies approved biologic treatments and existing off-label regimens as alternatives. An oral medicine can offer practical advantages, yet prescribing depends on patient characteristics, clinical experience and reimbursement. The relevant commercial test is whether LUPKYNIS continues to earn a useful place in treatment, including in combinations, as the field evolves. Source

The international arrangement is a partnership rather than a second sales force. Under the December 2020 agreement Otsuka develops and commercializes oral voclosporin in Japan, the European Union, the United Kingdom, Switzerland and several other European countries; Aurinia received a $50 million upfront payment and is entitled to regulatory and commercial milestones and royalties of 10% to 20% on net sales in those territories. A separate 2022 supply agreement has Aurinia selling LUPKYNIS inventory to Otsuka at cost plus a margin and sharing capacity at the dedicated manufacturing plant. That is why license, collaboration and royalty revenue, $3.808 million in the June quarter, sits alongside product sales, and why changes in Otsuka orders can move both revenue and gross margin. Source

The supply chain is also concentrated. Voclosporin is made at a dedicated Lonza facility, and the 10-K names Catalent as the sole supplier for encapsulation. Neither point signals a problem today; both are reasons why a single manufacturing interruption would matter more to Aurinia than to a company with several products. Source

03 The next operating checkpoint and the 2026 outlook

On August 6, 2026, Aurinia maintained full-year total-revenue guidance of $315–325 million and net product-sales guidance of $305–315 million. These are company forecasts for the year ending December 31, not guaranteed receipts. Against first-half product sales of $152.975 million, the product outlook implies a calculated $152.025–162.025 million in the second half, or an average of roughly $76.013–81.013 million per remaining quarter. Source Source

That comparison makes the next earnings release informative. June-quarter product sales of $79.412 million fall within that implied quarterly range, but repeating one quarter is not the same as meeting the annual target. Seasonality, the number of cartons sold, channel orders, rebates and treatment persistence can alter the relationship. What matters is whether the next results preserve a credible path through the range and whether cash follows revenue. Source

The August update also said research expense should increase as development progresses, while selling, general and administrative expense was expected to remain substantially consistent with the previous year. The operating test is therefore a balance: maintain the established franchise while spending more on the next opportunities. An earnings beat produced primarily by temporary accounting benefits would carry a different implication from sustained product demand. Source

On October 5, 2026 the investor page listed no upcoming event. The next quarterly report is an operating checkpoint, with its publication date to be announced; last year’s earnings date is not a reliable guide. The established year-end sales objective is the dated financial reference, while clinical and legal developments can arrive independently of an earnings call. Source Source

A simple sensitivity shows what the range requires. If third-quarter product sales matched the June quarter at $79.412 million, the fourth quarter would need $72.613 million to reach the bottom of the range and $82.613 million to reach the top. If the third quarter instead grew by the same 8.0% seen between the first and second quarters, it would come to roughly $85.7 million and the top of the range would be within reach without further growth in the fourth quarter. Both paths are Merlintrader calculations, not company forecasts; quarterly sales have not moved in a straight line in past years. Source

Timing is not fixed either. Aurinia reported its second quarter on August 6, 2026, six days later than the July 31 date of the prior year, and announced last year’s third-quarter report only one day ahead, on November 3, 2025, for November 4. A reader should therefore not treat early November as a scheduled date until the company announces one. Source

04 Product growth, margins and the quality of earnings

June-quarter product sales of $79.412 million were up from $66.574 million a year earlier. First-half product sales reached $152.975 million versus $126.545 million. The company attributed growth chiefly to more cartons sold to specialty pharmacies as penetration increased. Calculated first-quarter 2026 product sales were $73.563 million, making the June quarter about 8.0% higher sequentially. The sequential comparison is derived from the six-month and quarterly figures, not a separate management forecast. Source

The June quarter produced $46.341 million of operating income and $37.414 million net income. However, the operating result included $6.234 million of other income, which the filing attributes to three items: a favorable foreign-exchange remeasurement of the Swiss-franc lease liability, a one-time payment that settled all future obligations under a former officer’s revenue-linked arrangement, and the reduction of an accrual related to shareholder matters. These items are economically different from selling additional medicine. A useful assessment therefore follows product revenue and operating cash alongside reported profit, without assuming every component of the quarter repeats. Source

Gross margin was approximately 92% in both the quarter and first half, according to the August filing. A year earlier the figures were 90% for the quarter and 88% for the half. The filing attributes the lower cost of revenue mainly to smaller sales of LUPKYNIS inventory to Otsuka, which carry a low gross margin. Product mix therefore matters: a higher consolidated margin can coexist with a smaller contribution from one supply activity. It does not necessarily mean that the price or manufacturing profitability of every unit improved. Source

The sales channel also deserves attention. Aurinia recognizes sales to specialty pharmacies, a specialty distributor and Otsuka; those accounting customers are not a count of patients completing treatment. Receivables were $41.138 million at June 30 and accrued rebates and fees were $40.330 million. Neither balance signals a problem by itself, but changes in collections and gross-to-net deductions can explain why commercial momentum and cash conversion diverge. Source

Rebate accruals deserve a second look. Accrued sales rebates and fees rose from $30.832 million at December 31, 2025 to $40.330 million at June 30, 2026, about 30.8%, while first-half product sales grew 21% year on year. The two figures are not directly comparable, because an accrual is a balance at one date and sales are a flow over six months, and the filing does not explain the change. Still, if accruals keep rising faster than sales, the gap between gross and net price would be widening, and that is the kind of pressure that would show up in revenue per carton before it showed up in prescriptions. The comparison is a Merlintrader calculation. Source

Profit is now taxed. Aurinia released its remaining valuation allowance on deferred tax assets in the fourth quarter of 2025, so the 2026 effective tax rate rose to 23.3% in the June quarter and 22.6% in the half, from 2.9% and 3.5% a year earlier. Net income growth therefore understates the pre-tax improvement: pre-tax income rose to $48.786 million from $22.156 million in the quarter. Most of the new tax charge is non-cash for now, a point developed in the next chapter. Source

The research budget is growing mainly through people. Of the $5.618 million increase in June-quarter research expense, $4.011 million was personnel cost, while contract research and developmental expense fell to $2.072 million from $2.522 million. In Merlintrader’s reading, that pattern fits a company building an internal development team ahead of larger trials, whose running costs would come later. Source

05 Cash generation: no artificial cash-burn countdown

At June 30, 2026, Aurinia held $179.732 million of cash and equivalents and $263.291 million of short-term investments. That gives a calculated $443.023 million excluding $0.100 million restricted cash. The company’s commonly reported $443.123 million total includes that restricted amount. These are June balances, not a statement of the bank account on the publication date. Source

Operating cash flow was positive $85.126 million for the first six months, compared with positive $45.541 million a year earlier. The calculated monthly average was therefore $14.188 million generated, not burned. Subtracting $0.039 million of property, equipment and intangible purchases leaves $85.087 million before financing activities and acquisitions. A conventional cash-runway calculation based on a negative burn would misdescribe this period. Source

That does not make every future commitment self-funding. The cash statement also records $7.058 million of finance-lease principal payments outside operating cash flow. After that principal and the small capital-purchase amount, the first-half operating surplus was a calculated $78.029 million before share repurchases and other financing flows. This provides a more useful capital-allocation reference than treating operating cash flow as entirely discretionary cash. Source

Management expects to fund future operations from existing resources or cash generated by the business, based on its current plan. It also retains the possibility of raising equity or debt if necessary. The practical question is whether sales growth and expense control continue to support that plan. A large cash balance protects flexibility; it cannot turn an unsuccessful development program into a productive investment. Source

Taxes are one reason operating cash was so strong. First-half income tax expense was $20.942 million, but cash paid for taxes was only $2.355 million, because $20.387 million of the charge was deferred tax, drawn against the deferred tax asset recognized when the valuation allowance was released. The asset still stood at $178.935 million at June 30, 2026, up from $176.194 million at December 31, 2025, but only because the Kezar acquisition brought in $23.128 million of deferred tax assets; that amount is matched by $23.128 million of deferred tax benefits recorded as a liability, which the company expects to recognize as a reduction of future tax expense. Excluding the Kezar component, the original asset has been drawn down by the deferred charge, and as it is used up a larger share of the tax expense will be paid in cash and the gap between net income and operating cash flow will narrow. The $18.587 million difference in the first half is a Merlintrader calculation. Source

The half was also uneven. The company reported $52.5 million of operating cash flow in the June quarter, which leaves about $32.6 million for the March quarter by subtraction. Quarterly operating cash flow can swing with the timing of collections, rebate payments and other working-capital items, so a single quarter is a weak basis for extrapolation in either direction. Source

06 Why cash rose while shares were repurchased

The June cash balance reflects more than earnings. In the first half of 2026, Aurinia spent $74.880 million in cash on its repurchase program, received $59.154 million from shares issued for equity awards and paid $26.454 million of tax withholding related to net settlements. The difference between the latter two is $32.700 million. These financing movements help explain why a company can repurchase substantial stock and still receive cash through employee equity activity. Source

The cash statement also includes a $5.212 million net cash inflow from acquiring Kezar, because acquired cash exceeded cash consideration at closing. Purchases and maturities of investments moved cash between different financial assets. They are not operating growth, nor a permanent source of cash available every half-year. Source

This is why the total liquidity comparison is more useful than cash alone. Cash, restricted cash and investments rose from $397.997 million at December 31, 2025 to $443.123 million at June 30, 2026, a calculated increase of $45.126 million. The company generated operating cash, allocated part of it to repurchases and lease payments, and had additional acquisition and award-related movements. Source

For subsequent results, the useful follow-up is the same bridge: operating generation, development spending, lease obligations, acquisitions, repurchases and equity issuance. Each component can be reasonable, but their combination determines whether the resources belonging to each share improve. A rising cash balance and a repurchase announcement are not two independent pieces of evidence of the same value creation.

The quarterly split of the share activity shows why the bridge needs to be read in full. In the March quarter Aurinia repurchased about 2.5 million shares and issued about 1.7 million for awards; in the June quarter it repurchased about 2.5 million but issued about 4.5 million for equity awards, with cash proceeds from shares issued for equity awards reaching $59.154 million for the half. The first half therefore combined a large buyback with large award issuance, and the second effect dominated in the June quarter. Source

07 Obligations behind the liquid balance sheet

At June 30, 2026, Aurinia’s finance-lease liability was $60.422 million, including $16.479 million classified as current. It principally relates to the dedicated Lonza manufacturing facility. The company has exclusive use through March 31, 2030 and pays a quarterly fixed facility fee of 3.6 million Swiss francs. That recurring commitment matters even though the balance sheet is not organized around a large bank borrowing or convertible bond. Source

The facility helps support supply security and production efficiency, but it also creates fixed costs and currency exposure. The dollar value of the obligation changes with the Swiss franc, and the June quarter’s favorable remeasurement is not itself cash earned from medicine. Trading conclusions should therefore distinguish the operating benefit of manufacturing capacity from accounting fluctuations in the associated liability. Source

The June accounts also include $3.714 million of operating-lease liabilities and a $3.7 million contingent-value-right liability associated with Kezar’s closing net cash. Further CVR payments depend on contractual events. The company can have a strong net financial position while still owing future cash under operating and acquisition agreements. Source

A credit-facility covenant countdown is not the central financial test in this balance sheet. The relevant commitments are the lease schedule, commercial supply, development spending and contingent acquisition payments. A later debt financing would introduce its own maturity and covenant analysis. For the present operating model, continued cash generation and disciplined allocation of that cash are the more immediate measures. Source

The lease schedule in the June filing shows the cash profile of that commitment: $8.955 million for the rest of 2026, $17.911 million in each of 2027, 2028 and 2029 and $4.478 million in 2030, $67.166 million in total before $6.744 million of imputed interest. In the annual report the company estimated that a 10% move in the Swiss franc against the dollar would change the value of the liability by about $6.9 million, using the December 31, 2025 balance. Currency therefore affects both reported profit and the dollar cost of each quarterly fee. Source Source

08 Shares, incentives and the actual effect of buybacks

Aurinia had 132.907 million shares issued and outstanding at June 30, 2026, compared with 132.323 million at the previous year-end. The later cover-page count was 133,051,168 at August 5. The fact that the June count increased despite repurchases is not a contradiction: exercises and other equity awards also added stock. The net ownership result is what matters to an existing shareholder. Source

The company repurchased about 5.0 million shares for $74.9 million including commissions and excise tax in the first half. Repurchased shares are cancelled under Alberta law. At June 30, approximately $86.634 million remained under the authorized program, excluding broker commissions. That is capacity the board may use, not a promise that all the remaining amount will be spent immediately or at an advantageous price. Source

At June 30, options outstanding were 5.844 million with a weighted-average exercise price of $12.16, and unvested performance and restricted units totaled 4.698 million. Those categories sum to a calculated 10.542 million awards, but they are not all currently issued shares, and conditions, forfeitures and exercises will affect the final result. Cash received from option exercises does not remove the corresponding change in ownership. Source

The company has unlimited authorized common shares under its corporate structure. That is legal capacity, not a forecast of issuance. The demonstrated sources of share-count change in the current financial statements are awards, exercises, the employee purchase plan and repurchases. Those movements and any new financing announcement are the direct indicators; a buyback does not eliminate every route to dilution. Source

The June quarter makes the point concrete. Shares outstanding rose from 130.771 million at March 31 to 132.907 million at June 30: about 4.536 million were issued for equity awards and 53,000 under the employee purchase plan, against 2.452 million repurchased. The company bought 1,977,966 shares in April at an average of $15.84 and 473,651 in May at $15.50, and none in June. Since purchases began on February 21, 2024, the program has retired 23.3 million shares for $213.4 million excluding commissions, an average of about $9.16 a share by Merlintrader calculation, out of a total authorization of $300 million approved in two $150 million steps in February 2024 and July 2025. Source

New awards continue. On June 4, 2026 each of four non-employee directors received a grant of 23,931 options at an exercise price of $15.67, vesting after one year, reported on Forms 4 filed June 8. Grants of this size are routine for a board, but they belong in the same ledger as buybacks when judging the net change in ownership. Source Forms 4

09 The Teva settlement: useful visibility with defined limits

The August 19, 2026 settlement resolves Aurinia’s patent dispute with Teva over its proposed generic voclosporin product. Teva stipulated that the two identified dosing patents, expiring in December 2037, are valid, enforceable and would be infringed by its commercial U.S. sales. Under the agreement, Teva may launch no earlier than December 7, 2036 unless specified contingencies allow an earlier date; FDA approval is also required. Source

The date is therefore specific to Teva and conditional. It is not a court ruling that prevents every competitor from entering before that day. The same announcement says litigation continues in the U.S. District Court for the District of New Jersey against seven other challengers: DifGen Pharmaceuticals; Dr. Reddy’s Laboratories and an affiliate; Galenicum Health; Hikma Pharmaceuticals USA; Lotus Pharmaceutical and an affiliate; Sandoz; and Zydus Pharmaceuticals (USA) and an affiliate. A favorable agreement with one party cannot settle those separate disputes by implication. Source

The economic benefit is greater visibility over one possible source of competition. If that visibility permits more reliable planning for investment and cash returns, it can matter beyond the legal headline. Its value nevertheless depends on the remaining cases, commercial demand and the actual time during which the product retains attractive economics.

Different patent dates should also remain distinct. The annual report describes composition-of-matter protection extending to October 2027 and dosing patents extending further. A short date associated with one patent is not automatically the date all protection ends; a long date attached to another patent is not a guarantee that it survives every challenge. The settlement stands on its own terms. Source Source

U.S. drug law adds a separate floor for the remaining cases. Because LUPKYNIS was approved as a new chemical entity and Aurinia sued each filer within 45 days of its notice letter, the annual report states that the FDA cannot approve these generic applications earlier than 7.5 years after approval of the LUPKYNIS new drug application, unless a district court first finds all asserted claims invalid, unenforceable or not infringed. The FDA approved LUPKYNIS on January 22, 2021, which places that point at about July 22, 2028, a Merlintrader calculation. It is the earliest date at which an approval could take effect under that rule, not a forecast that any generic will launch then. Source FDA

One more legal matter sits outside the patent cases. On November 2, 2025 Aurinia sued Dr. George Tidmarsh in federal court in Maryland for defamation and injurious falsehood, alleging that he personally made false statements regarding voclosporin; the company seeks damages. The June-quarter filing reports no material developments in the legal proceedings described in the annual report. The case concerns Aurinia’s allegations, which have not been decided by a court. Source Source

10 What the clinical evidence establishes

The original AURORA 1 publication in 2021 reported complete renal response at one year in 73 of 179 patients assigned voclosporin, about 41%, versus 40 of 178 assigned placebo, about 23%, both with background treatment; p<0.0001. These 357 randomized patients support the established efficacy case. They do not imply that every patient responds or that the treatment can be evaluated separately from the accompanying regimen. Source

In that publication, serious adverse events occurred in about 21% of treated patients in each group. A comparable trial safety profile is different from an absence of risk. The annual report lists reduced kidney filtration, hypertension and infections among relevant adverse reactions. The commercial case depends on clinicians finding an acceptable balance between benefit, monitoring and tolerability for individual patients. Source Source

On June 4, 2026, Aurinia presented a new analysis of the AURORA 1 safety population: 356 patients, 178 in each group. The composite of a renal-related event or death had a hazard ratio of 0.47, a 53% relative risk reduction, with p=0.0007. This is an additional analysis of an existing study, not a newly completed pivotal trial enrolling another population. Source

The distinction between the composite and its components is decisive. Death alone had a hazard ratio of 0.19 with p=0.0929 in that presentation, which does not meet the usual 0.05 threshold. The headline therefore must not become a claim that mortality was significantly reduced by 81%. The composite result supports the renal-protection narrative, while the individual mortality result remains uncertain. Source

The other components of the June composite pointed the same way: treatment failure had a hazard ratio of 0.45 with p=0.0062, and worsening proteinuria a hazard ratio of 0.22 with p<0.0001. The death component, by contrast, appears to rest on very few events, a Merlintrader inference: the 2021 publication counted six deaths across both arms, one with voclosporin and five with placebo, none judged related to treatment by investigators. With so few events a hazard ratio can look large and still be statistically uncertain, which is what p=0.0929 says. The analysis was presented at the EULAR 2026 congress years after the trial ended and is not the trial’s primary endpoint, which was complete renal response at week 52. Source Source

11 PRESERVE and aritinercept: development rather than an invented deadline

Aurinia announced initiation of PRESERVE on July 6, 2026. It is studying LUPKYNIS with established biologic approaches in lupus nephritis. The commercial rationale is understandable: a useful role in combination treatment could preserve relevance as prescribing changes. Starting the study, however, supplies no comparative result and does not establish that each combination improves outcomes or has acceptable tolerability. Source

The announcement’s six-month response assessment is a patient follow-up period, not a promise to publish full results six months after the press release. Enrollment, treatment and analysis must occur before a meaningful readout. Until an actual results announcement or a company-defined reporting window, that catalyst has no fixed date. Source

Aritinercept is a separate early-development asset, designed to inhibit BAFF and APRIL. The June 30, 2025 Phase 1 announcement covered 61 healthy participants. It reported mean immunoglobulin reductions by day 28 of up to 48% for IgA, 55% for IgM and 20% for IgG. These are pharmacodynamic observations in healthy people, without a patient-efficacy p-value in that release. They are a reason to continue development, not proof that autoimmune disease improves. Source

The annual report additionally describes anti-drug antibodies in most participants at the higher dose levels, without an observed effect on the measured safety, pharmacokinetic or pharmacodynamic parameters. That limited observation does not establish the consequences of repeated treatment over longer periods. By the August 2026 results update, clinical development had begun in four potential indications. The next meaningful value change requires patient data that justify continued spending, rather than treating the number of programs as a result. Source Source

The trial registry adds detail the press releases leave out. PRESERVE, listed as NCT07611214, is a single-group, open-label Phase 4 study: every patient receives LUPKYNIS with one of the three biologics and there is no control arm. The registry lists an actual start date of April 22, 2026, earlier than the July 6 announcement of the study’s initiation; it plans about 150 patients, measures complete renal response at 24 weeks and lists an estimated primary completion date of March 2, 2029. A study of this design can describe response rates on combinations, but it cannot by itself show how much each drug adds. Source

For aritinercept, the only patient study found on ClinicalTrials.gov on October 5, 2026 is NCT07596901, a randomized, quadruple-masked Phase 1/2 study in generalized myasthenia gravis with about 81 planned patients. It started on April 22, 2026, its primary outcome is safety and tolerability, and its estimated primary completion is March 2, 2029. The company has said development has begun in four potential indications; the other three were not identifiable in the registry under the drug’s name. Source Source

12 Kezar: completed transaction, contingent economics

Aurinia completed the Kezar acquisition on May 11, 2026. Cash consideration at closing was $51.599 million, while cash acquired was $56.811 million. The difference explains the $5.212 million net acquisition cash inflow in the first-half cash statement. It does not make the acquired assets free: the transaction also included contingent rights and obligations that affect who receives future value. Source Source

Former Kezar shareholders received $6.955 cash per common share plus a non-transferable CVR. The rights can receive specified proceeds related to development or disposition of zetomipzomib, certain collaboration or asset-sale proceeds, and closing net cash above $50 million after defined expenses. The June financial statements recorded $3.7 million for the excess-cash component. Future economics therefore cannot all be assigned to Aurinia shareholders without considering those rights. Source

The transaction adds optionality, but it should be valued separately from LUPKYNIS’s established operating contribution. Acquiring a clinical asset is not a regulatory endorsement and does not create a scheduled approval. The relevant milestones are a disclosed development decision, credible patient evidence, the cost of reaching the next stage and the share of economic value retained after contingent payments.

The financial scale is also useful context. This acquisition did not require treating the June liquid balance as if it had disappeared into a large net cash purchase. At the same time, a favorable initial cash bridge does not settle future research expense. The disciplined test is whether management can turn the acquired rights into useful value at a reasonable incremental cost, with transparent economics for existing shareholders.

The accounting confirms the scale. Total purchase consideration was $55.488 million: $51.599 million in cash, $3.7 million for the contingent value rights already considered probable and $0.189 million of transaction costs. The deal was treated as an asset acquisition, with in-process research and development valued at only $0.449 million. Beyond the excess-cash payment, the rights cover proceeds tied to zetomipzomib, to Kezar’s collaboration with Everest Medicines and to the earlier sale of its Sec61 program to Enodia Therapeutics; none of those is recorded because the company does not consider them probable and estimable. Source

Zetomipzomib also brings a clinical history that belongs in any reading of the contingent value. Kezar’s annual report for 2025 discloses that its PALIZADE Phase 2b trial in lupus nephritis was placed on FDA clinical hold in October 2024 after 15 serious adverse events, including four deaths — one in the placebo arm, two at 30 mg and one at 60 mg — and that the trial was terminated; Kezar attributed the deaths to severe disease manifestations, co-morbidities or systemic infections. In our reading, any future development of the molecule under Aurinia will be judged against that record, which is a safety question before it is a commercial one. Source

13 Management, ownership and short interest

Kevin Tang became chief executive in the March 23, 2026 management transition, alongside Michael Hearne as CFO. The June financial statements identify Tang as CEO and board chair. His investment role makes capital allocation particularly relevant, but management’s ownership does not remove commercial, clinical or governance risk. Source Source

The Tang group reported beneficial ownership of 13,044,106 common shares in its June 4 filing, stated as 10.0% using that filing’s denominator. Measured against the 133,051,168 shares on the August 5 cover, the same holding is about 9.8%, a Merlintrader calculation. The group bought 814,606 shares in the open market between May 29 and June 2, 2026, at weighted-average prices of $15.28 to $15.35, and on June 2 wrote 10,000 put contracts, collecting $1.65 per share of premium, that could oblige it to buy another one million shares at $15 until January 15, 2027. Those puts are a potential obligation, not shares already owned. A separate holder, the ILJIN group controlled by Chin Kyu Huh, reported on August 26 that its ownership had fallen below 5% after sales on August 20: 5,911,237 shares attributed to Mr. Huh, about 4.4%, plus 465,769 and 167,062 shares held by his adult daughters. Mr. Huh disclaims beneficial ownership of his daughters’ shares, and each daughter disclaims the holdings of the other, of her father and of the ILJIN companies. ILJIN is no longer required to report further changes on Schedule 13D. Source Source Source Source

Chief legal officer Stephen Robertson’s September 10 sale of 11,939 shares at a weighted-average $15.95 and August 21 sale of 20,975 at $16.97 were automatic sales to cover tax on performance-unit vesting, according to the Form 4 footnotes. They are not discretionary bearish sales. The economic transfer is real; the disclosed reason matters to its interpretation. The Form 144 filed on August 21 covered up to 47,000 shares for the same tax purpose, more than the 20,975 actually sold that day, and Robertson reported 588,848 shares still held after the September sale. Source Source Source

Nasdaq reported short interest of 8,576,505 shares at the September 15, 2026 settlement, equal to 11.1 days of average daily volume. That is about 6.4% of the 133,051,168 shares outstanding on the August 5 cover, a Merlintrader calculation, and down from 9,589,939 shares at the June 30 settlement. Short interest is published twice a month with a lag, so the figure describes positions on its settlement date. Finviz data as of October 2, 2026, which are third-party figures not confirmed in filings, show 118.13 million shares of float, institutional ownership of 58.32% and insider ownership of 11.21%. The shares closed at $15.83 on October 2, 2026, close to the prices at which the chief executive’s group bought in late May and early June and above the $15 strike of its puts. None of these figures predicts a squeeze or substitutes for the company’s actual share count. Source Source Source

14 Red flags, next checks and bottom line

The main commercial warning would be growth that no longer converts into operating cash, particularly if rebate pressure or competition weakens the product economics. The main capital-allocation warning would be cash commitments growing faster than the demonstrated value of the pipeline. Research expense already rose to $13.050 million in the June quarter from $7.432 million a year earlier, and management expects further development spending. The increase can be productive, but it needs evidence. Source

Patent protection is another independent variable. The Teva settlement removes one dispute on agreed terms; it does not erase the other challengers or establish universal exclusivity. Clinical interpretation also needs discipline: a composite renal analysis is not a proven mortality benefit, and a healthy-volunteer biomarker response is not an established treatment effect in autoimmune patients. Source Source Source

The next operating report should show product demand against the August full-year outlook, cash generated after the recurring obligations, and the net effect of repurchases and equity awards on shares outstanding. Separate clinical updates should be judged on actual participant numbers, effect size and safety. Legal updates should identify the specific party and terms rather than replace them with a single distant expiry date.

Several dated reference points are already on the record. January 15, 2027 is the expiry of the chief executive group’s $15 puts. Around July 22, 2028 the 7.5-year bar on approval of the challenged generic applications runs out by Merlintrader calculation, unless a court rules against all the asserted claims first. October 2027 is the end of the extended composition-of-matter patent, December 7, 2036 the earliest agreed Teva entry and December 2037 the expiry of the two dosing patents. The PRESERVE and aritinercept registry entries both point to March 2029 for primary completion, as estimates that can move. Source Source Source

Aurinia’s strongest attribute is that the operating business already produces cash. Its unresolved question is how durable that cash will be and how effectively it will finance growth or return capital. The shareholder case would strengthen if commercial performance, retained cash and credible development evidence advanced together. It would weaken if an attractive balance-sheet headline concealed declining franchise economics or commitments that failed to produce value. Source Source